3 unchanged sentences
The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines.
−Removed: With our core operations strategically located in four limited-license medical and adult-use markets, Vireo Growth cultivates and manufactures cannabis products in environmentally friendly greenhouses and other facilities and distributes these products through our growing network of Green Goods™ and other Vireo Growth branded retail dispensaries, as well as third-party dispensaries in the markets in which our subsidiaries hold operating licenses.
−Removed: As of March 4, 2025, Vireo Growth, through its subsidiaries, has licenses and operates in three states, consisting of Maryland, Minnesota, and New York.
−Removed: Additionally, the Company has non-operating assets and liabilities in Nevada and Massachusetts.
−Removed: As of March 4, 2025, we retail cannabis products in 14 dispensaries located across Maryland (2), Minnesota (8), and New York (4) and wholesales cannabis products, through third-party companies, in Maryland, Minnesota, and New York.
−Removed: Our registered office is located at 1000 Cathedral Place, 925 West Georgia Street, Vancouver, British Columbia V6E 3L2.
−Removed: Our head office is located at 207 South Ninth Street, Minneapolis, Minnesota 55402.
+Added: With our core operations strategically located in six markets, Vireo Growth cultivates and manufactures cannabis products in environmentally friendly greenhouses and other facilities and distributes these products through our growing network of Green Goods™ and other Vireo Growth branded retail dispensaries, as well as third-party dispensaries in the markets in which our subsidiaries hold operating licenses.
+Added: As of March 17, 2026, Vireo Growth, through its subsidiaries, has licenses and operates in six states, consisting of Maryland, Minnesota, Missouri, Nevada, New York, and Utah.
+Added: As of March 17, 2026, we retail cannabis products in 36 dispensaries located across Maryland (2), Minnesota (8), Missouri (11), Nevada (10), New York (4), and Utah (1) and wholesales cannabis products, through third-party companies, in Maryland, Minnesota, Missouri, Nevada, New York, and Utah.
+Added: Our registered office is located at Suite 2200-1021 West Hastings Street, Vancouver, British Columbia V6E 0C3.
+Added: Our corporate office is located at 207 South Ninth Street, Minneapolis, Minnesota 55402.
History of the Company
9 unchanged sentences
On June 9, 2021, we changed our name to “Goodness Growth Holdings, Inc.” On June 25, 2024, we changed our name to “Vireo Growth Inc.”
−Removed: Arrangement Agreement
−Removed: We and Verano Holdings Inc.
−Removed: (" Verano ") entered into an Arrangement Agreement dated January 31, 2022, later amended on June 22, 2022 (combined, the " Arrangement Agreement ").
−Removed: Pursuant to the Arrangement Agreement, Verano agreed, among other things, to acquire all of the outstanding shares of Vireo.
−Removed: We received notice from Verano on October 13, 2022, of Verano's purported termination of the Arrangement Agreement.
−Removed: We believe that Verano has no factual or legal basis to justify or support its purported grounds for termination of the Arrangement Agreement, and on October 13, 2022, we commenced an action in the Supreme Court of British Columbia against Verano.
−Removed: See “ Item 3.
−Removed: Legal Proceedings – Verano ” and “ Item 1A.
−Removed: Risk Factors — We are involved in litigation with Verano, the outcome of which is uncertain .”
−Removed: Merger Agreements with Deep Roots, Proper and Wholesome and MOU with Bill’s Nursery
−Removed: On December 18, 2024, we entered into Merger Agreements (as defined herein) with respect to a business combination with each of (i) Deep Roots Holdings, Inc., a Nevada corporation (“Deep Roots”) (the “Deep Roots Merger”);
−Removed: (ii) Proper Holdings Management, Inc.
−Removed: and NGH Investments, Inc., both Missouri corporations (together, “Proper”) (the “Proper Mergers”);
−Removed: and (iii) WholesomeCo, Inc., a Delaware corporation (“Wholesome”) (the “Wholesome Merger” and, collectively with the Deep Roots Merger and the Proper Mergers, the “Mergers”).
−Removed: Each Merger is an all-share transaction whereby, at the closing of each applicable transaction, (i) a new wholly-owned subsidiary of the Company would merge with and into Deep Roots, (ii) a new wholly-owned subsidiary of the Company would merge with and into Wholesome, and (ii) the Proper entities would each merge with and into new wholly-owned subsidiaries of the Company.
−Removed: None of the Deep Roots Merger, the Proper Mergers or the Wholesome Merger is contingent on the completion of any of the other Mergers.
−Removed: The consideration to be paid to acquire each of Deep Roots, Proper and Wholesome is based, in each case, in part on an estimated multiple of a 2024 “Reference EBITDA”, which is pro-forma for pending acquisitions as well as planned new retail openings and expansion projects, and a US$0.52 share reference price for the Company’s subordinate voting shares.
−Removed: Pursuant to the Merger Agreements, former stockholders of each of Deep Roots, Proper and Wholesome may qualify for earnout payments made with the Company’s Subordinate Voting Shares following December 31, 2026, based on each target’s Adjusted EBITDA (as defined in the applicable Merger Agreement) growth compared to such target’s Reference EBITDA (at a 4x multiple), adjusted for incremental debt and certain other matters, respectively, and paid out using a share price for the Company’s subordinate voting shares of the higher of US$1.05 or the 20-day volume weighted average price of the Company’s Subordinate Voting Shares on the Canadian Securities Exchange, converted to United States Dollars based on the average exchange rate posted by the Bank of Canada as of the end of each trading day during such 20-day period, as reported by Bloomberg Finance L.P.
−Removed: (“VWAP”) as of December 31, 2026.
−Removed: Reference EBITDA for Deep Roots, Proper and Wholesome are US$31.0 million, US$31.0 million, and US$16.0 million, respectively.
−Removed: EBITDA growth is defined as the increase between Reference EBITDA and the higher of 2026 Adjusted EBITDA or trailing nine-month annualized Adjusted EBITDA as of December 31, 2026.
−Removed: In no event shall the number of earnout shares issued under each Merger Agreement exceed the number of shares issued as closing merger consideration in each Merger Agreement.
−Removed: Each of the Merger Agreements provides for the clawback of up to 50% of the upfront merger consideration (excluding, in the case of Proper and Wholesome, the amounts attributable to Arches, as defined below) on December 31, 2026, if, in each case, (a) 2026 Adjusted EBITDA underperforms 96.5% of the Reference EBITDA, and (b) retail revenue market share or EBITDA margin for 2026 is less (or lower) than 2024 and (c) the 20-day VWAP as of December 31, 2026 is greater than US$1.05 per share.
−Removed: The amount of shares subject to a clawback would be equal to the Acquisition Multiple (as defined in each Merger Agreement) for each of Deep Roots, Proper and Wholesome, respectively, multiplied by the EBITDA shortfall, and subject to certain other adjustments set forth in the applicable Merger Agreement, divided by US$0.52 per share, not to exceed 50% of the upfront consideration.
−Removed: In connection with the Wholesome Merger Agreement (as defined herein) and Proper Merger Agreement (as defined herein), the Company will include in the stock merger consideration calculation an amount equal to (i) US$11,860,800 for the stockholders of Wholesome and (ii) US$2,139,200 for the stockholders of Proper for all of the outstanding equity interests in Arches IP, Inc.
−Removed: (“Arches”) owned by Wholesome and Proper, respectively.
−Removed: Subject to the terms and conditions of the Wholesome Merger Agreement and the Proper Merger Agreement, each of Wholesome, Proper and Arches option holders are collectively entitled to earnout payments based on performance of Arches, based on the greater of US$37.5 million or 5x certain revenue percentages of Arches, with such revenue percentage amounts measured at the higher of trailing-twelve-month or nine-month annualized amounts as of December 31, 2026, paid out using a share price for the Company’s subordinate voting shares at the higher of US$1.05 or 20-day VWAP as of December 31, 2026.
−Removed: In connection with each of the Merger Agreements, the Company will enter into an Investor Rights Agreement with the persons receiving the Company’s subordinate voting shares in the Mergers.
−Removed: Each Investor Rights Agreement will require the Company in certain circumstances to prepare and file with the SEC a registration statement covering the resale of the Company’s subordinate voting shares issued pursuant to the Merger Agreements, in each case following the expiration of the initial 12 month lock-up period following the closing of the transactions under each Merger Agreement.
−Removed: Each Investor Rights Agreement will also provide such persons with certain piggyback registration rights in certain circumstances.
−Removed: The closing of each of the Mergers is subject to the closing conditions described below and contained in the Merger Agreements.
−Removed: The Company cannot predict the actual date on which the Mergers will be completed, or if the Mergers will be completed at all.
−Removed: Pursuant to rules adopted by the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), a Schedule 14C information statement will be prepared by the Company and filed with the SEC and mailed to the shareholders of the Company relating to shareholder approval of the issuance of the Company’s Subordinate Voting Shares in the Mergers and any other approvals required under the rules of the Canadian Stock Exchange, which is expected to be obtained by written consent of the shareholders.
−Removed: Deep Roots Merger Agreement
−Removed: On December 18, 2024, the Company, Vireo DR Merger Sub Inc., a Nevada corporation (“DR Merger Sub”), Deep Roots and Shareholder Representative Services LLC, a Colorado limited liability company (“Shareholder Representative”) entered into an Agreement and Plan of Merger (the “Deep Roots Merger Agreement”), pursuant to which, following the closing of the Deep Roots Merger, the Company will issue a number of Subordinate Voting Shares in consideration for all of the issued and outstanding shares of Deep Roots equal to the amount of the Estimated Closing Merger Consideration (as defined in the Deep Roots Merger Agreement) divided by US$0.52, subject to a post-closing purchase price adjustment with respect to certain of the estimated items included in the Estimated Closing Merger Consideration.
−Removed: In general, the Estimated Closing Merger Consideration is based upon a multiple of the $31 million Reference EBITDA described above, adjusted for certain items as described in the definition of Closing Merger Consideration in the Deep Roots Merger Agreement, including cash, indebtedness, transaction expenses, working capital, and tax items.
−Removed: Subject to the terms and conditions of the Deep Roots Merger Agreement, at the closing, DR Merger Sub will merge with and into Deep Roots, with Deep Roots surviving as a wholly-owned subsidiary of the Company.
−Removed: The Subordinate Voting Shares of the Company to be issued by the Company to the stockholders of Deep Roots pursuant to the Deep Roots Merger Agreement will be issued in reliance upon the exemptions from registration provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act.
−Removed: The Deep Roots Merger Agreement contains customary representations, warranties and covenants, including covenants relating to the conduct of Deep Roots’ businesses during the period between the execution of the Deep Roots Merger Agreement and the completion of the Deep Roots Merger, subject to certain exceptions.
−Removed: The obligation of the parties to consummate the Deep Roots Merger is subject to a number of conditions, including but not limited to receipt of the approval of the Deep Roots Merger by holders of a majority of the outstanding shares of Deep Roots entitled to vote thereon, receipt of the approval of the Company’s shareholders as required by the Canadian Stock Exchange by (i) in the case of a shareholder meeting, a majority of the votes cast at such meeting or (ii) in the case of action by written consent of shareholders, by a majority of the outstanding voting power of shares of the Company, the closing of an equity investment in the Company in an aggregate amount at least equal to US$75 million, the appointment by the Board of Directors of the Company (the “Board”) of John Mazarakis as the Company’s Chief Executive Officer and Co-Executive Chairman, delivery of certain documents and agreements, the accuracy of the representations and warranties of the parties (subject to the materiality standards contained in the Deep Roots Merger Agreement), the receipt of certain regulatory consents and approvals (including under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and approval of the Canadian Stock Exchange), delivery of investor rights agreements and lock-up agreements, Deep Roots having a minimum amount of cash as of the closing, the absence of Deep Roots stockholders exercising appraisal rights, and the absence of a Material Adverse Effect or Parent Material Adverse Effect (as each such term is defined in the Deep Roots Merger Agreement).
−Removed: Pursuant to the Deep Roots Merger Agreement, the stockholders of Deep Roots will at or prior to the closing enter into lock-up agreements with the Company providing that each such person, for a period of up to 33 months, may not, subject to customary exceptions, offer, issue, sell, transfer or otherwise dispose of the Company’s Subordinate Voting Shares issued as closing merger consideration without the prior written consent of the Company.
−Removed: The lock-up agreements provide that the Subordinate Voting Shares acquired by the stockholders of Deep Roots pursuant to the Deep Roots Merger Agreement as closing merger consideration are subject to a lock-up release schedule of 7.5% of shares 12-months post-closing of the Deep Roots Merger, 10% of shares 18-months and 21-months post-closing, 17.5% of shares 24-months post-closing, 15% of shares 27-months post-closing and 20% of shares 30-months and 33-months post-closing.
−Removed: In addition, all such Subordinate Voting Shares of the Company then held by such persons are subject to lock-up during the 6-month period ending December 31, 2026.
−Removed: In addition, any of the Company’s Subordinate Voting Shares issued in connection with the earnout payments described above would be subject to lock-up periods following issuance of such earnout shares, with a 20% release per quarter ending at 15 months post-issuance.
−Removed: The Deep Roots Merger Agreement also contains customary indemnification obligations of the Company and Deep Roots, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require the Company or Deep Roots to pay a termination fee equal to US$6,376,240.
−Removed: The Deep Roots Merger Agreement also provides the parties with certain remedies, including the right to specific performance, in the event of a breach of obligations under the Deep Roots Merger Agreement.
−Removed: The foregoing description of the Deep Roots Merger Agreement is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the Deep Roots Merger Agreement, which is included as Exhibit 2.2 to this Form 10-K and is incorporated herein by reference.
−Removed: A copy of the Deep Roots Merger Agreement has been included to provide shareholders with information regarding its terms and conditions and is not intended to provide any factual information about the Company or Deep Roots.
−Removed: The representations, warranties and covenants contained in the Deep Roots Merger Agreement have been made solely for the benefit of the parties to the Deep Roots Merger Agreement, and are not intended as statements of fact to be relied upon by the Company’s shareholders, but rather as a way of allocating the risk between the parties to the Deep Roots Merger Agreement in the event the statements therein prove to be inaccurate.
−Removed: Statements made in the Deep Roots Merger Agreement have been modified or qualified by certain confidential disclosures that were made between the parties in connection with the negotiation of the Deep Roots Merger Agreement, which disclosures are not reflected in the Deep Roots Merger Agreement attached hereto.
−Removed: Moreover, such statements may no longer be true as of a given date and may apply standards of materiality in a way that is different from what may be viewed as material by shareholders.
−Removed: Accordingly, shareholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or Deep Roots.
−Removed: Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Deep Roots Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.
−Removed: The Company acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements in this Annual Report on Form 10-K not misleading.
−Removed: Important information regarding certain risks associated with the Merger Agreements and Mergers are discussed under the heading “Item 1A.
−Removed: Risk Factors — Risks Related to the Mergers ” of this Annual Report on Form 10-K.
−Removed: Proper Merger Agreement
−Removed: On December 18, 2024, the Company, Vireo PR Merger Sub Inc., a Missouri corporation (“PR Merger Sub”), Vireo PR Merger Sub II Inc., a Missouri corporation (“PR Merger Sub II”), Proper Holdings, LLC (“Proper Parent”), Proper and Shareholder Representative entered into an Agreement and Plan of Merger (the “Proper Merger Agreement”), pursuant to which, following the closing of the Proper Mergers, the Company will issue a number of Subordinate Voting Shares in consideration for all of the issued and outstanding shares of each of the Proper entities equal to the amount of the Estimated Closing Merger Consideration (as defined in the Proper Merger Agreement) divided by US$0.52, subject to a post-closing purchase price adjustment with respect to certain of the estimated items included in the Estimated Closing Merger Consideration.
−Removed: In general, the Estimated Closing Merger Consideration is based upon a multiple of the $31 million Reference EBITDA described above, adjusted for certain items as described in the definition of Closing Merger Consideration in the Proper Merger Agreement, including the amounts attributable to Arches as described above, cash,
−Removed: indebtedness, transaction expenses, working capital, and tax items.
−Removed: Subject to the terms and conditions of the Proper Merger Agreement, at the closing, NGH Investments, Inc.
−Removed: will merge with and into PR Merger Sub and Proper Holdings Management, Inc.
−Removed: will merge with and into PR Merger Sub II, with each of PR Merger Sub and PR Merger Sub II surviving as wholly-owned subsidiaries of the Company.
−Removed: The Subordinate Voting Shares of the Company to be issued by the Company to Proper Parent as the stockholder of Proper pursuant to the Proper Merger Agreement will be issued in reliance upon the exemptions from registration under the Securities Act provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act.
−Removed: The Proper Merger Agreement contains customary representations, warranties and covenants, including covenants relating to the conduct of Proper’s businesses during the period between the execution of the Proper Merger Agreement and the completion of the Proper Mergers, subject to certain exceptions.
−Removed: The obligation of the parties to consummate the Proper Mergers is subject to a number of conditions, including but not limited to receipt of the approval of the Company’s shareholders a required by the Canadian Stock Exchange by (i) in the case of a shareholder meeting, a majority of the votes cast at such meeting or (ii) in the case of action by written consent of shareholders, by a majority of the outstanding voting power of shares of the Company, the closing of an equity investment in the Company in an aggregate amount at least equal to US$75 million, the appointment by the Board of John Mazarakis as the Company’s Chief Executive Officer and Co-Executive Chairman, the appointment by the Board of John Pennington as a director of the Company, the transfer of the CA Credit Agreement (as defined in the Proper Merger Agreement) to NGH Investments, Inc.
−Removed: and Proper Holdings Management, Inc., the completion of the Holdings Restructuring (as defined in the Proper Merger Agreement), delivery of certain documents and agreements, the accuracy of the representations and warranties of the parties (subject to the materiality standards contained in the Proper Merger Agreement), the receipt of certain regulatory consents and approvals (including under the HSR Act and approval of the Canadian Stock Exchange), delivery of an investor rights agreement and lock-up agreement, Proper having a minimum amount of cash as of the closing, and the absence of a Material Adverse Effect or Parent Material Adverse Effect (as each such term is defined in the Proper Merger Agreement).
−Removed: Pursuant to the Proper Merger Agreement, Proper Parent will at or prior to the closing enter into a lock-up agreement with the Company (and each of the members or other transferees of Proper Parent who would ultimately receive any of the Company’s Subordinate Voting Shares from Proper Parent, prior to receipt of any such shares, would enter into a lock-up agreement with the Company) providing that each such person, for a period of up to 33 months, may not, subject to customary exceptions, offer, issue, sell, transfer or otherwise dispose of the Company’s Subordinate Voting Shares issued as closing merger consideration without the prior written consent of the Company.
−Removed: The lock-up agreements provide that the Subordinate Voting Shares acquired by Proper Parent and/or the members of Proper Parent pursuant to the Proper Merger Agreement as closing merger consideration are subject to a lock-up release schedule of 7.5% of shares 12-months post-closing of the Proper Mergers, 10% of shares 18-months and 21-months post-closing, 17.5% of shares 24-months post-closing, 15% of shares 27-months post-closing and 20% of shares 30-months and 33-months post-closing.
−Removed: In addition, all such Subordinate Voting Shares of the Company then held by such persons are subject to lock-up during the 6-month period ending December 31, 2026.
−Removed: In addition, any of the Company’s Subordinate Voting Shares issued in connection with the earnout payments described above would be subject to lock-up periods following issuance of such earnout shares, with a 20% release per quarter ending at 15 months post-issuance.
−Removed: The Proper Merger Agreement also contains customary indemnification obligations of the Company or Proper, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require the Company or Proper to pay a termination fee equal to US$4,631,012.
−Removed: The Proper Merger Agreement also provides the parties with certain remedies, including the right to specific performance, in the event of a breach of obligations under the Proper Merger Agreement.
−Removed: The foregoing description of the Proper Merger Agreement is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the Proper Merger Agreement, which is included as Exhibit 2.3 to this Annual Report on Form 10-K and is incorporated herein by reference.
−Removed: A copy of the Proper Merger Agreement has been included to provide shareholders with information regarding its terms and conditions, and is not intended to provide
−Removed: any factual information about the Company or Proper.
−Removed: The representations, warranties and covenants contained in the Proper Merger Agreement have been made solely for the benefit of the parties to the Proper Merger Agreement, and are not intended as statements of fact to be relied upon by the Company’s shareholders, but rather as a way of allocating the risk between the parties to the Proper Merger Agreement in the event the statements therein prove to be inaccurate.
−Removed: Statements made in the Proper Merger Agreement have been modified or qualified by certain confidential disclosures that were made between the parties in connection with the negotiation of the Proper Merger Agreement, which disclosures are not reflected in the Proper Merger Agreement attached hereto.
−Removed: Moreover, such statements may no longer be true as of a given date and may apply standards of materiality in a way that is different from what may be viewed as material by shareholders.
−Removed: Accordingly, shareholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or Proper.
−Removed: Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Proper Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.
−Removed: The Company acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements in this Annual Report on Form 10-K not misleading.
−Removed: Wholesome Merger Agreement
−Removed: On December 18, 2024, the Company, Vireo WH Merger Sub Inc., a Delaware corporation (“WH Merger Sub”), Wholesome and Shareholder Representative entered into an Agreement and Plan of Merger (the “Wholesome Merger Agreement” and, together with the Deep Roots Merger Agreement and the Proper Merger Agreement, the “Merger Agreements”), pursuant to which, following the closing of the Wholesome Merger, the Company will issue a number of Subordinate Voting Shares in consideration for all of the issued and outstanding shares of Wholesome equal to the amount of the Estimated Closing Merger Consideration (as defined in the Wholesome Merger Agreement) divided by US$0.52, subject to a post-closing purchase price adjustment with respect to certain of the estimated items included in the Estimated Closing Merger Consideration.
−Removed: In general, the Estimated Closing Merger Consideration is based upon a multiple of the $16 million Reference EBITDA described above, adjusted for certain items as described in the definition of Closing Merger Consideration in the Wholesome Merger Agreement, including the amounts attributable to Arches as described above, cash, indebtedness, transaction expenses, working capital, and tax items.
−Removed: Subject to the terms and conditions of the Wholesome Merger Agreement, at the closing, WH Merger Sub will merge with and into Wholesome, with Wholesome surviving as a wholly-owned subsidiary of the Company.
−Removed: The Subordinate Voting Shares of the Company to be issued by the Company to the stockholders of Wholesome pursuant to the Wholesome Merger Agreement will be issued in reliance upon the exemptions from registration under the Securities Act provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act.
−Removed: The Wholesome Merger Agreement contains customary representations, warranties and covenants, including covenants relating to the conduct of Wholesome’s businesses during the period between the execution of the Wholesome Merger Agreement and the completion of the Wholesome Merger, subject to certain exceptions.
−Removed: The obligation of the parties to consummate the Wholesome Merger is subject to a number of conditions, including but not limited to receipt of the approval of the Wholesome Merger by holders of a majority of the outstanding shares of Wholesome entitled to vote thereon, receipt of that approval of the Company’s shareholders as required by the Canadian Stock Exchange by (i) in the case of a shareholder meeting, a majority of the votes cast at such meeting or (ii) in the case of action by written consent of shareholders, by a majority of the outstanding voting power of shares of the Company, the closing of an equity investment in the Company in an aggregate amount at least equal to US$75 million, the appointment by the Board of John Mazarakis as the Company’s Chief Executive Officer and Co-Executive Chairman, delivery of certain documents and agreements, the accuracy of the representations and warranties of the parties (subject to the materiality standards contained in the Wholesome Merger Agreement), the receipt of certain regulatory consents and approvals (including under the HSR Act and approval of the Canadian Stock Exchange), delivery of investor rights agreements and lock-up agreements, Wholesome having a minimum amount of cash as of the closing, the absence of Wholesome stockholders exercising appraisal rights, and the absence of a Material Adverse Effect or Parent Material Adverse Effect (as each such term is defined in the Wholesome Merger Agreement).
−Removed: Pursuant to the Wholesome Merger Agreement, the stockholders of Wholesome will at or prior to the closing enter into lock-up agreements with the Company providing that each such person, for a period of up to 33 months, may not, subject to customary exceptions, offer, issue, sell, transfer or otherwise dispose of the Company’s Subordinate Voting Shares issued as closing merger consideration without the prior written consent of the Company.
−Removed: The lock-up agreements provide that the Subordinate Voting Shares acquired by the stockholders of Wholesome pursuant to the Wholesome Merger Agreement as closing merger consideration are subject to a lock-up release schedule of 7.5% of shares 12-months post-closing of the Wholesome Merger, 10% of shares 18-months and 21-months post-closing, 17.5% of shares 24-months post-closing, 15% of shares 27-months post-closing and 20% of shares 30-months and 33-months post-closing.
−Removed: In addition, all such Subordinate Voting Shares of the Company then held by such persons are subject to lock-up during the 6-month period ending December 31, 2026.
−Removed: In addition, any of the Company’s Subordinate Voting Shares issued in connection with the earnout payments described above would be subject to lock-up periods following issuance of such earnout shares, with a 20% release per quarter ending at 15 months post-issuance.
−Removed: The Wholesome Merger Agreement also contains customary indemnification obligations of the Company or Wholesome, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require the Company or Wholesome to pay a termination fee equal to US$3,394,217.
−Removed: The Wholesome Merger Agreement also provides the parties with certain remedies, including the right to specific performance, in the event of a breach of obligations under the Wholesome Merger Agreement.
−Removed: The foregoing description of the Wholesome Merger Agreement is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the Wholesome Merger Agreement, which is included as Exhibit 2.4 to this Annual Report on Form 10-K and is incorporated herein by reference.
−Removed: A copy of the Wholesome Merger Agreement has been included to provide shareholders with information regarding its terms and conditions, and is not intended to provide any factual information about the Company or Wholesome.
−Removed: The representations, warranties and covenants contained in the Wholesome Merger Agreement have been made solely for the benefit of the parties to the Wholesome Merger Agreement, and are not intended as statements of fact to be relied upon by the Company’s shareholders, but rather as a way of allocating the risk between the parties to the Wholesome Merger Agreement in the event the statements therein prove to be inaccurate.
−Removed: Statements made in the Wholesome Merger Agreement have been modified or qualified by certain confidential disclosures that were made between the parties in connection with the negotiation of the Wholesome Merger Agreement, which disclosures are not reflected in the Wholesome Merger Agreement attached hereto.
−Removed: Moreover, such statements may no longer be true as of a given date and may apply standards of materiality in a way that is different from what may be viewed as material by shareholders.
−Removed: Accordingly, shareholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or Wholesome.
−Removed: Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Wholesome Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.
−Removed: The Company acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements in this Annual Report on Form 10-K not misleading.
−Removed: Memorandum of Understanding with Bill’s Nursery, Inc.
−Removed: Effective as of December 18, 2024, the Company and Bill’s Nursery, Inc.
−Removed: (“Bill’s”) entered into a binding Memorandum of Understanding (the “MOU”).
−Removed: Subject to the terms and conditions of the MOU, the Company intends to negotiate and enter into an Agreement and Plan of Merger with Bill’s (the “Bill’s Merger Agreement”), pursuant to which a newly incorporated subsidiary of the Company would merge with and into Bill’s, with Bill’s surviving as a wholly-owned subsidiary of the Company (the “Proposed Transaction”).
−Removed: The principal terms of the MOU are as follows:
−Removed: · the Company would issue 210,000,000 subordinate voting shares of the Company at a per-share value of US$0.52 per share in consideration of all of the issued and outstanding shares of Bill’s;
−Removed: · the Bill’s Merger Agreement would be expected to provide (i) stockholders of Bill’s with an earn-out payment to be reasonably agreed upon between the Company and Bill’s, (ii) a clawback of up to 95,000,000 subordinate voting
−Removed: shares of the Company, subject to Bill’s performance during the fiscal year 2026 and (iii) customary covenants with respect to the operation of Bill’s and the Company from and after the closing of the Proposed Transaction;
−Removed: · Bill’s and the Company will each be responsible for their respective costs, expenses and fees incurred in connection with the negotiation, preparation and execution of the Bill’s Merger Agreement and the completion of the Proposed Transaction;
−Removed: · during the period commencing upon the full execution of the MOU and ending at 5:00 p.m., Eastern Standard Time, on February 23, 2025 (the “Exclusivity Period”), neither Bill’s nor its subsidiaries nor anyone acting on their respective behalf will engage in any efforts to, and will not knowingly, directly or indirectly, through any officer, employee, director, representative, parent, affiliate, broker, advisor or otherwise:
−Removed: (a) solicit, initiate or entertain the submission of inquiries, proposals or offers from any corporation, partnership, person or other entity, person or group relating to, directly or indirectly, (i) any acquisition or purchase of, or any debt, convertible debt, equity or profit sharing interest, voting rights or control rights in (A) Bill’s, (B) any of the Bill’s subsidiaries or controlled affiliates or (C) any operating company that has a management services agreement with Bill’s or any of its subsidiaries or controlled affiliates, or (ii) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, of any of the assets of Bill’s, its subsidiaries or controlled affiliates (other than sales of inventory on commercial terms in the ordinary course of business) (each an “Acquisition Proposal”);
−Removed: or (b) participate or engage in, in each case directly or indirectly, any negotiations or other discussions relating to any Acquisition Proposal;
−Removed: · on December 20, 2024, the Company paid to Bill’s an amount in cash equal to US$1 million and, in the event that the parties do not execute and deliver the Bill’s Merger Agreement by the end of the Exclusivity Period, Bill’s will pay to the Company an amount in cash equal to US$1.25 million within two business days of the end of such period.
−Removed: If the parties execute and deliver the Bill’s Merger Agreement, the US$1 million paid by the Company will be repaid by Bill’s in connection with the closing of the Proposed Transaction.
−Removed: · On February 21, 2025, the Company entered into a letter agreement (the “Second Letter Agreement”) with Bill’s Nursery, Inc., whereby the parties confirmed that they have paused their negotiations concerning the Definitive Agreement, as defined in the MOU effective as of December 18, 2024 between the parties, and as such the exclusivity period has expired.
−Removed: The parties also agreed in the Second Letter Agreement to amend the provision in Section 4 of the MOU providing that, in the case the parties do not execute and deliver a Definitive Agreement, that Bill’s Nursery, Inc.
−Removed: shall pay to the Company US$1.25 million within two business days.
−Removed: The Second Letter Agreement amends Section 4 to provide that such payment shall be in the amount of US$1 million to be paid within 45 calendar days.
−Removed: Except as so modified, the parties’ obligations under the MOU remain otherwise unchanged.
−Removed: The foregoing description of the MOU is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the MOU, which is included as Exhibit 10.80 to this Annual Report on Form 10-K and the Letter Agreement dated January 23, 2025 between the Company and Bill’s, which is included as Exhibit 10.86 to this Annual Report on Form 10-K, both of which are incorporated herein by reference.
+Added: Completed Mergers
+Added: On December 18, 2024, the Company entered into definitive merger agreements to complete merger transactions with each of Deep Roots Holdings, Inc., a Nevada corporation (“Deep Roots”), Proper Holdings Management, Inc.
+Added: and NGH Investments, Inc., both Missouri corporations (together, “Proper”), and WholesomeCo, Inc., a Delaware corporation (“Wholesome”) (collectively, the “Mergers”).
+Added: Each of the Mergers was structured as an all-share transaction pursuant to which, at the applicable closing, newly formed wholly owned subsidiaries of the Company merged with the respective target entities, with each target surviving as a wholly owned subsidiary of the Company in connection with the Deep Roots
+Added: and Wholesome Mergers, and the wholly-owned subsidiaries of the Company surviving in connection with the Proper Mergers.
+Added: Each of the Mergers closed during the year ended December 31, 2025.
+Added: Specifically, the Company completed the merger with Wholesome on May 12, 2025, the Merger with Proper on June 5, 2025, and the Merger with Deep Roots on June 6, 2025.
+Added: Strategic Rationale
+Added: The Mergers were undertaken to enhance the Company’s scale, operational efficiencies, and geographic diversification, and to strengthen its competitive position in existing and new markets.
+Added: Each Merger expanded the Company’s cultivation, manufacturing, retail, and intellectual property capabilities and added experienced management teams and workforces.
+Added: The Company believes the Mergers position it for improved operating leverage and long-term growth.
+Added: Consideration Structure
+Added: The consideration paid in connection with each Merger consisted primarily of the Company’s subordinate voting shares and was based, in part, on an estimated multiple of each target’s 2024 closing EBITDA, pro forma for pending acquisitions, planned retail openings, and expansion projects, using a reference share price of $0.52 per subordinate voting share.
+Added: The merger agreements also provide for potential earnout payments payable in subordinate voting shares based on post-closing performance metrics, as well as clawback provisions under certain circumstances, all as further described in Note 3 of the consolidated financial statements.
+Added: Accounting Treatment
+Added: Each of the Mergers was accounted for as a business combination under applicable accounting standards.
+Added: The Company recorded goodwill and identifiable intangible assets in connection with the acquisitions, reflecting the expected synergies, assembled workforce, market expansion opportunities, and other benefits of combining the acquired businesses with the Company’s operations.
+Added: Additional information regarding the purchase accounting, contingent consideration, and pro forma financial information is included in the notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
+Added: Pending Transactions
+Added: In addition to the completed mergers described above, the Company has entered into definitive agreements and arrangements relating to several pending transactions that had not closed as of December 31, 2025.
+Added: Schwazze Transaction
+Added: On October 10, 2025, Vireo Health of Colorado, LLC, a wholly owned subsidiary of the Company (“ VHC ”), entered into a restructuring support agreement (“ RSA ”) with Medicine Man Technologies, Inc.
+Added: d/b/a Schwazze, a Nevada corporation (“ Schwazze ”), certain of Schwazze’s subsidiaries, the beneficial holders of certain seller notes secured by a first priority security interest in substantially all the assets owned by SBUD LLC, a wholly owned subsidiary of Schwazze, and certain other parties.
+Added: The RSA was entered into in connection with the Company’s acquisition of a majority of the outstanding principal amount of Schwazze’s 13% senior secured convertible notes due December 7, 2026 for aggregate consideration of approximately 117.9 million subordinate voting shares valued at $78.0 million.
+Added: The RSA contemplates a restructuring of Schwazze and its subsidiaries, including the sale of certain assets through a public disposition of collateral.
+Added: On November 13, 2025, a public auction of Schwazze’s collateral was completed, at which the credit bid made on behalf of VHC and the other noteholders was the winning bid.
+Added: Following the auction, Schwazze entered into an asset purchase agreement with a newly formed entity that as of the closing of the transaction is expected to ultimately be majority owned by the Company.
+Added: Subject to regulatory approvals and other customary closing conditions, the assets subject to the asset purchase agreement are expected to be transferred in exchange for the assumption of certain specified liabilities and the
+Added: discharge of the senior secured notes included in the credit bid (collectively, the “ Schwazze Transaction ”).
+Added: The transaction had not closed as of December 31, 2025.
+Added: Colorado Dispensary Assets
+Added: On December 16, 2025, the Company entered into an asset purchase agreement, through its wholly owned subsidiary, Vireo Health, Inc., to acquire certain assets, liabilities, and properties used in cannabis dispensaries operating in the State of Colorado with PharmaCann Inc., a Delaware corporation (“ PharmaCann ”) and related entities.
+Added: Under the terms of the agreement, the Company expects to issue subordinate voting shares with an estimated value of approximately $49.0 million, subject to certain adjustments (the “ PharmaCann Transaction ”).
+Added: The transaction had not closed as of December 31, 2025.
+Added: On December 22, 2025, the Company entered into an agreement and plan of merger to acquire Eaze Inc., a Delaware corporation (“ Eaze ”), in a business combination transaction (the “ Eaze Merger ”).
+Added: Eaze is a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado.
+Added: The transaction is expected to represent Vireo’s entry into the California and Florida cannabis markets.
+Added: In California, Eaze maintains a significant delivery-focused presence, operating four co-located retail and delivery facilities and eight delivery-only locations, providing coverage across most major metropolitan areas in the state.
+Added: In Florida, Eaze is the sixth-largest cannabis retailer, with 39 active dispensaries and approximately 64,000 square feet of cultivation canopy, with capacity for future expansion.
+Added: The transaction will also expand Vireo’s retail operations in Colorado through the addition of 14 dispensaries.
+Added: Pursuant to the merger agreement, following the closing of the transaction, the Company will issue subordinate voting shares as consideration for all of the issued and outstanding equity interests of Eaze.
+Added: The estimated closing consideration is approximately $47.0 million, subject to customary post-closing adjustments.
+Added: The merger agreement also provides for potential earnout consideration payable in subordinate voting shares based on Eaze’s future financial performance, subject to contractual limitations.
+Added: The transaction is subject to customary closing conditions, including regulatory approvals and approval by Eaze’s stockholders, and had not closed as of December 31, 2025 .
Description of the Business
Overview of the Company
−Removed: Vireo is the holding company for Vireo U.S., a United States-based multi-state cannabis company that operates through its license-holding subsidiaries, with significant operations in three core markets:
−Removed: Maryland, Minnesota, and New York.
−Removed: In June 2023, we sold our operations in the New Mexico market, where we previously conducted business.
+Added: Vireo is the holding company for Vireo U.S., a United States-based multi-state cannabis company that operates through its license-holding subsidiaries, with significant operations in the following core markets:
+Added: Maryland, Minnesota, Missouri, New York, Nevada and Utah.
We are committed to a science-focused approach to providing patients and adult-use customers with high-quality cannabis products.
−Removed: Our operations include cultivating cannabis in environmentally friendly environments, manufacturing
−Removed: pharmaceutical-grade cannabis extracts, and distributing our products through both Company-owned and third-party dispensaries.
+Added: Our operations include cultivating cannabis in environmentally friendly environments, manufacturing pharmaceutical-grade cannabis extracts, and distributing our products through both Company-owned and third-party dispensaries.
We currently serve thousands of customers each month.
All of the states in which we operate have adopted legislation to permit the use of cannabis products for medicinal purposes to treat specific conditions and diseases, which is referred to as medical cannabis or medical marijuana.
−Removed: In addition, all of the states in which we operate have adopted legislation to permit the use of cannabis products by adults ages 21 and older, which is referred to as recreational- or adult-use cannabis or recreational- or adult-use marijuana.
+Added: In addition, with the exception of Utah, all of the states in which we operate have adopted legislation to permit the use of cannabis products by adults ages 21 and older, which is referred to as recreational- or adult-use cannabis or recreational- or adult-use marijuana.
Our principal locations and type of operation are listed below:
47 unchanged sentences
Opened in 2020
−Removed: Caliente, Nevada
−Removed: Held for sale
+Added: Kansas City, Missouri
+Added: Fully operational dispensary facility
Acquired in 2025
−Removed: Johnstown, New York
−Removed: Fully operational cultivation and processing facility
−Removed: Opened in 2016
+Added: Louis, Missouri
+Added: Fully operational cultivation and processing facility and dispensary facilities
+Added: Acquired in 2025
+Added: Festus, Missouri
+Added: Fully operational, manufacturing and transport facility
+Added: Acquired in 2025
+Added: Bridgeton, Missouri
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: Ellisville, Missouri
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: Olivette, Missouri
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: House Springs, Missouri
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: Warrenton, Missouri
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: Kirkwood, Missouri
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: Las Vegas, Nevada
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: Henderson, Nevada
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: North Las Vegas, Nevada
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: Mesquite, Nevada
+Added: Fully operational cultivation and processing facility and dispensary facility
+Added: Acquired in 2025
+Added: Pahrump, Nevada
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
+Added: West Wendover, Nevada
+Added: Fully operational dispensary facility
+Added: Acquired in 2025
Colonie, New York
10 unchanged sentences
Opened in 2016
+Added: Johnstown, New York
+Added: Fully operational indoor cultivation and processing facility
+Added: Opened in 2016
+Added: Upland, Pennsylvania
+Added: Land acquired as part of a litigation settlement;
+Added: in development
+Added: Acquired in 2025
+Added: Centerville, Utah
+Added: Fully operational indoor cultivation and processing facility
+Added: Acquired in 2025
+Added: Bountiful, Utah
+Added: Fully operational courier and home delivery facility
+Added: Acquired in 2025
+Added: Grantsville, Utah
+Added: Fully operational outdoor cultivation facility
+Added: Acquired in 2025
Our mission is to provide patients and consumers with best-in-class cannabis products and expert advice, informed by medicine and science.
1 unchanged sentence
We have developed proprietary cannabis strains, cultivation methods, carbon dioxide extraction, ethanol extraction, and other processes related to the production, refinement, and packaging of cannabis products.
−Removed: We have documented the relevant processes in the form of standard operating procedures and work instructions, which are only shared with third parties when absolutely required and then only upon receipt of written non-disclosure agreements.
+Added: We have documented the relevant processes in the form of standard operating procedures and work instructions, which are shared with third parties only in limited circumstances and then only upon receipt of written non-disclosure agreements.
We have sought and continue to seek to protect our trademark and service mark rights.
Because the cultivation, processing, possession, transport and sale of cannabis and cannabis-related products remain illegal under the Controlled Substances Act (as defined below) we are not able to fully protect our intellectual property at the federal level.
−Removed: As a result, we have
−Removed: sought and continue to seek federal registrations in limited classes of goods and services and have obtained several state registrations.
+Added: As a result, we have sought and continue to seek federal registrations in limited classes of goods and services and have obtained several state registrations.
The Cannabis Industry and Business Lines of the Company
−Removed: According to market research projections by cannabis researcher Brightfield Group, U.S.
+Added: According to market research projections by cannabis researcher Grand View Research, U.S.
sales of legal cannabis are expected to reach over $76 billion by 2030.
−Removed: As described further below, United States federal law now bifurcates the legality of “hemp” (defined as any part of the Cannabis sativa L plant —including any seeds, derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers thereof, whether growing or not —with a tetrahydrocannabinol (“ THC ”) concentration of less than 0.3% on a dry weight basis) from “marihuana” (also commonly known as “marijuana”).
+Added: As described further below, United States federal law now bifurcates the legality of “hemp” (currently defined as any part of the Cannabis sativa L plant —including any seeds, derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers thereof, whether growing or not —with a delta-9 tetrahydrocannabinol (“ THC ”) concentration of less than 0.3% on a dry weight basis) from “marihuana” (also commonly known as “marijuana”).
For purposes of this filing, the term “cannabis” means “marihuana” as set forth in the Controlled Substances Act (21 U.S.C.
13 unchanged sentences
Cultivation Facilities
−Removed: We have rights to operate cultivation facilities in three states.
−Removed: Although pricing pressure for dried flower in several mature cannabis markets has led some operators to eschew cultivation, in certain markets the transition from medical-only to adult-use cannabis has increased wholesale market prices significantly.
−Removed: We believe that our cultivation operations provide certain other benefits, including:
−Removed: We continually seek ways to optimize our growing processes and minimize expenses.
−Removed: By having control over our own cultivation, we can reduce input costs and maximize margins.
−Removed: We believe that production at scale is critical to drive down unit cost.
−Removed: Product Availability :
−Removed: Control over our cultivation facilities allows us to monitor and update the product mix in our dispensaries to meet evolving demand, particularly regarding strain selection and diversity.
−Removed: Quality Assurance :
−Removed: Quality and safety are critically important to us and our customers.
−Removed: Controlling our growing processes greatly reduces the risk of plant contamination or infestation, and we believe that consistently high-quality products can demand higher retail prices.
−Removed: Our focus on quality, potency, strain diversity and scalable production is vital because we believe that the wholesale market for cannabis plant material will become increasingly price-competitive over time as more companies enter this industry segment.
−Removed: We believe that manufacturers and retailers that source high-quality, low-cost plant material will have a significant advantage in the medium and long term.
−Removed: We have rights to operate cultivation facilities in three states.
+Added: We have rights to operate cultivation facilities in six states.
Although pricing pressure for dried flower in several mature cannabis markets has led some operators to eschew cultivation, in certain markets the transition from medical-only to adult-use cannabis has increased wholesale market prices significantly.
10 unchanged sentences
We believe that manufacturers and retailers that source high-quality, low-cost plant material will have a significant advantage in the medium and long term.
−Removed: Cultivation and Production Facilities
−Removed: Except for our bifurcated cultivation-only and production-only facilities in Maryland, we operate combined cultivation and production facilities.
−Removed: Each cultivation and production facility focuses primarily on the development of cannabis products and dried cannabis plant material for medical and other consumer use, as well as the research and development of new strains of cannabis.
−Removed: At all our facilities, we focus on consumer safety and maintaining strict quality control.
−Removed: The methods we employ result in consistent production of high-quality products and minimize product recalls and complaints from patients and adult-use customers.
−Removed: Our cultivation business line operates year-round, although operations and sales trends in select markets exhibit seasonal fluctuations.
−Removed: In some regions, outdoor cultivation opportunities arise seasonally, and sales may be impacted during summer and winter months.
−Removed: Additionally, promotional activity often increases around specific industry events and holidays, including April 20, July 10 and Green Wednesday (the Wednesday before Thanksgiving).
−Removed: We operate the following cultivation and production facilities as of the close of business on March 4, 2025:
−Removed: We operate one cultivation facility of approximately 110,000 square feet total, with 42,814 square feet of greenhouse flowering canopy, and one production facility of approximately 30,000 square feet.
−Removed: In March 2021, we transferred the cultivation license from our formerly co-located cultivation and processing facility to another facility consisting of approximately 110,000 square feet of greenhouse space and associated land and buildings.
−Removed: The production operation remains at the original combined cultivation and processing facility.
−Removed: We have a number of customers;
−Removed: our results of operations and financial results in Maryland are not dependent upon sales to one or a few major customers.
−Removed: Currently operate one cultivation and production facility of approximately 90,000 square feet total, with 38,400s square feet of greenhouse flowering canopy.
−Removed: Additional 110,000 square foot operation with 30,000 square feet of indoor flowering canopy is under construction and intended primarily to support the adult-use market when adult-use sales commence.
−Removed: We have a large number of customers;
−Removed: our results of operations and financial results in Minnesota are not dependent upon sales to one or a few major customers.
−Removed: Currently operate approximately 160,000 square feet of cultivation and production space total, with 13,280 square feet of operational indoor flowering canopy.
−Removed: An additional 29,040 square feet of indoor flowering canopy is under construction and intended primarily to support the adult-use market.
−Removed: We purchase a modest portion of our manufactured products inventory from several other registered organizations.
−Removed: We have a large number of customers;
−Removed: our results of operations and financial results in New York are not dependent upon sales to one or a few major customers.
Manufacturing
−Removed: We manufacture, assemble, and package cannabis finished goods across a variety of product segments:
+Added: The Company manufactures , assembles, and packages branded cannabis finished goods across a variety of product segments:
flower and trim;
6 unchanged sentences
balms and topical bars.
−Removed: We have wholesale operations in Maryland, Minnesota, and New York.
+Added: We have wholesale operations in Maryland, Minnesota, Missouri, Nevada, New York, and Utah.
Manufactured products are sold to third parties, where allowed, and are also distributed to Company-owned and operated retail dispensaries.
2 unchanged sentences
No individual supplier represents a significant portion of our purchases or poses a material risk to our operations.
−Removed: Principal Products or Services
−Removed: Our brands include:
−Removed: ● Vireo Spectrum™ brand pre-filled distillate vaporizer pre-rolls, flower, pens and cartridges, syringes, bulk oil, edibles, softgels, tablets, oral solutions, oral spray, topical bars, and topical balms;
−Removed: ● Vireo Selects™ brand distillate and live terpene vaporizer pens, disposable vaprozier pens, and syringes
−Removed: ● 1937™ brand distillate and live terpene vaporizer pens and cartridges, disposable vaporizer pens, flower and trim, and dabbable concentrates;
−Removed: ● Boundary Waters™ pre-roll products, RSO Gummies, Half Gram Vapes, disposable vaporizer pens, and hemp derived beverages;
−Removed: ● Hi-Color™ edibles;
−Removed: ● Kings and Queens™ concentrates, including live and cured resin badder, budder, sugar, and sauce;
−Removed: and Infused Pre-rolls and Live Resin Pre-filled Vaporizer Cartridges
−Removed: ● Simple™ brand distillate vaporizer cartridges, disposable vaporizer cartidges, and flower
−Removed: Westwater™ Topical Balms
−Removed: ● Small A$$ Bud™ flower
−Removed: ● Hi*AF™ distillate vaporizer disposable pens and pre-filled cartridges and hemp derived beverages
−Removed: ● Various other flower and trim brands.
−Removed: The following table shows which principal manufactured products we currently sell at our dispensaries in our various markets:
−Removed: Principal Products
−Removed: 1937 Vape Cartridges;
−Removed: 1937 Disposable Vape Pens, 1937 Concentrates;
−Removed: 1937 Pre-Rolls;
−Removed: 1937 Pre-Pack Flower;
−Removed: 1937 Bulk Flower;
−Removed: 1937 Bulk Trim;
−Removed: Hi-Color™ edibles;
−Removed: 1937 RSO Syringes, Kings and Queens™ concentrates, Hi-Roller Infused Pre-Roll Kits, infused pre-rolls, and vape cartridges;
−Removed: Small A$$ Buds bulk flower, Hi*AF™ distillate vaporizer disposable pens and pre-filled cartridges
−Removed: Vireo Selects Vape Cartridges and Syringes, Vireo Spectrum Vapes, Vireo Spectrum Flower and Pre-Rolls, Boundary Waters Pre-Rolls, Vireo Spectrum Capsules;
−Removed: Vireo Spectrum Tincture;
−Removed: Vireo Spectrum Oral Solution;
−Removed: Vireo Spectrum Oral Spray;
−Removed: Vireo Spectrum Syringe/Bulk Oil;
−Removed: Vireo Spectrum Tablet;
−Removed: Vireo Spectrum Topical Balm;
−Removed: Vireo Spectrum Topical Bar, Simple Vape Cartridges and Bulk Flower, Dr.
−Removed: Westwater Topical Balms, Boundary Waters RSO Gummies, Boundary Waters Vapes, Boundary Waters Flower, Boundary Waters Hemp Derived Beverages, Hi*AF Hemp Derived Beverages, HiTide Hemp Derived Beverages, HiCOLOR Hemp Derived Edibles, Limited Salad Flower, Vireo Spectrum Edibles.
−Removed: Vireo Selects Vape Cartridges, Vireo Spectrum Vape Cartridges;
−Removed: Hi-Color™ edibles, Vireo Spectrum Syringes/Bulk Oil;
−Removed: Vireo Spectrum Softgel;
−Removed: Moonlight Softgel;
−Removed: Vireo Spectrum Oral Solution;
−Removed: Vireo Spectrum Oral Spray;
−Removed: Vireo Spectrum Balm;
−Removed: Vireo Spectrum Flower;
−Removed: Vireo Spectrum Pre-Rolls, Simple Vape Cartridges, Simple 14g/28g Small Bud Flower, Hi*AF Vape Cartridges, Hi*AF Disposable Vape Pens, 1937 Indoor Flower.
+Added: Significant Customers
+Added: Our customers include legal state-licensed cannabis stores within each U.S.
+Added: state in which we operate.
+Added: Vireo is not dependent upon a single customer, or a few customers, and the loss of any one or more of our customers would not have a material adverse effect on the business.
+Added: No customer accounted for 10% or more of our consolidated net revenue during the fiscal years ended December 31, 2025 or 2024.
Retail Strategy
−Removed: We have invested substantial resources in developing customer-friendly store designs and floorplans.
−Removed: In 2020, we began constructing new dispensaries using a modern layout and refreshed color scheme tied to the Green Goods™ trademark, and we have also been converting existing dispensaries to this new theme.
−Removed: Members of our management team have experience in real estate development, which has enabled us to secure premium locations for some of our dispensaries.
−Removed: We typically target locations with high foot traffic, good visibility, and proximity to densely populated residential areas.
−Removed: We also elevate factors such as location characteristics, vehicular traffic, local demographics, and competitor proximity when selecting retail locations.
+Added: We have invested substantial resources in developing customer-friendly dispensary store designs and floorplans that emphasize efficient traffic flow, accessibility, and a consistent customer experience.
+Added: Since 2020, we have constructed new dispensaries using modern layouts and updated design elements, and we have selectively refreshed existing dispensaries to align with evolving brand strategies.
+Added: Members of our management team have experience in real estate development, which has enabled us to secure premium locations for our dispensaries.
+Added: We typically target locations with high foot traffic, strong visibility, and proximity to densely populated residential areas, and we evaluate factors such as location characteristics, vehicular traffic patterns, local demographics, and proximity to competitors when selecting retail sites.
Principal Business Objectives
−Removed: Our principal business objectives over the next 12-month period include achieving positive operating cash flow through cost discipline, operational excellence, and product quality;
−Removed: improving the quality and efficiency of flower production in Maryland and Minnesota;
−Removed: pursuing non-core asset divestitures;
−Removed: managing the balance sheet with capital partners to grow into being a strong credit.
+Added: Our principal business objectives over the next 12-month period include delivering positive operating cash flow through continued cost discipline, operational excellence, and enhancements in product quality and consistency across our markets.
+Added: We remain focused on optimizing the performance of our cultivation, production, and retail operations and leveraging opportunities to deliver value to our customers and investors.
+Added: We intend to manage our balance sheet prudently and work collaboratively with capital partners to strengthen our credit profile and financial flexibility.
+Added: In addition, we will continue to evaluate strategic opportunities to deploy capital in pursuit of disciplined, high-quality acquisitions and other initiatives that align with our operating capabilities, expand our geographic reach, and support long-term growth.
Employees and Human Capital Resources
As of February 6, 2026 we had 612 employees, 520 of whom were full-time employees.
−Removed: Certain of our employees in Maryland, Minnesota and New York are represented by local offices of the United Food and Commercial Workers International Union (“ UFCW ”).
+Added: Certain of our employees in Maryland, Minnesota, New York, and Utah are represented by local offices of the United Food and Commercial Workers International Union or the American Federation of Labor and Congress of Industrial Organizations.
The collective bargaining agreements with the employees in these states expire as follows:
2 unchanged sentences
November 22, 2026
−Removed: New York (Security)
−Removed: October 31, 2024
New York (non-drivers)
2 unchanged sentences
December 31, 2027
−Removed: Our collective bargaining agreements in New York and Maryland have expired and negotiations are in progress.
−Removed: We anticipate a resolution and consider our overall relationships with our employees, UFCW, and Local 811 to be positive.
+Added: February 29, 2028
Our human capital objectives focus on attracting, developing, retaining, and engaging a talented workforce.
3 unchanged sentences
Our former research and development activities primarily focused on developing new, innovative, and patent-protectable products for the cannabis market.
−Removed: These efforts have focused on novel cannabinoid formulations as well as accessory products designed to improve the cannabis consumption experience.
−Removed: We also experimented with plant spacing and nutrient blends, cannabis variety trialing and improved pest management techniques.
−Removed: We also engaged in research and development activities focused on developing new extracted or infused products.
+Added: These efforts have resulted in novel cannabinoid formulations and accessory products that enhance the cannabis consumption experience.
+Added: We also explored plant spacing, nutrient blends, cannabis variety trials, and advanced pest management techniques, as well as the development of new extracted and infused products.
Patents and Trademarks
−Removed: We hold two patents for “Tobacco Products with Cannabinoid Additives and Methods for Reducing the Harm Associated with Tobacco Use” (US Patents 10,369,178 and 10,702,565) and have a number of other patents pending with the United States Patent and Trademark Office (“ USPTO ”).
−Removed: We have successfully registered the trademarks Vireo Health®, Green Goods®, and 1937® with the USPTO.
+Added: We hold the following patents:
+Added: Patent Number
+Added: Tobacco Products with Cannabinoid Additives and Methods for Reducing the Harm Associated with Tobacco Use
+Added: Tobacco Products with Cannabinoid Additives and Methods for Reducing the Harm Associated with Tobacco Use
+Added: Dosage Forms, Packaging & Vaporization Device
+Added: Cannabinoid Enriched Personal Lubricant
+Added: Oral Cannabinoid Delivery Formulations with Mouthfeel Experience Enhances
+Added: Cannabis Based Moist Snuff
+Added: We have successfully registered the trademarks Vireo Health®, Green Goods®, 1937®, Deep Roots Harvest®, WholesomeCo®, The Source® with the United States Patent and Trademark Office (“ USPTO ”), and have a number of other trademarks pending with the USPTO.
Competitive Conditions and Position
6 unchanged sentences
Aside from current direct competition, other operators that are sufficiently capitalized to enter the Company’s markets through new licensure or acquisitive growth are also considered potential competitors.
−Removed: Similarly, if and to the extent we continue to enter new markets, we will encounter new direct competitors.
+Added: Similarly, to the extent we continue to enter new markets, we will encounter new direct competitors.
See “ Item 1A.
−Removed: Risk Factors — Risks Related to our Business Operations — We face intense competition in a new and rapidly growing industry by other licensed companies with more experience and financial resources than we have and by unlicensed and unregulated participants.
+Added: Risk Factors — Risks Related to our Business and Operations — The cannabis industry is rapidly evolving and is experiencing intense competition from licensed, unlicensed and well-capitalized market participants offering alternative competitive products and could also be further bolstered by state law regimes.
Regulation of Cannabis in the United States
2 unchanged sentences
Federal Regulation
−Removed: We currently directly derives a substantial portion of our revenues from the cannabis industry in certain U.S.
+Added: We currently directly derive a substantial portion of our revenues from the cannabis industry in certain U.S.
states, which industry is illegal under U.S.
−Removed: As of December 31, 2024, the Company is directly involved (through licensed subsidiaries) in both the medical and adult-use cannabis industry in the states of New York, Minnesota, and Maryland as permitted within such states under applicable state law.
+Added: As of December 31, 2025, the Company is directly involved (through licensed subsidiaries) in the medical and/or adult-use cannabis industry in the states of New York, Minnesota, Maryland, Missouri, Nevada, and Utah as permitted within such states under applicable state law.
federal law, however, continues to prohibit cannabis activities.
Supreme Court has ruled that Congress has the constitutional authority to enact the existing federal prohibition on cannabis.
−Removed: The federal government regulates drugs under the Controlled Substances Act, which places controlled substances—including marijuana—in specific schedules.
+Added: The federal government regulates drugs under the Controlled Substances Act (the “ CSA ”) which places controlled substances—including marijuana—in specific schedules.
Marijuana is classified as a Schedule I drug, meaning it is defined as a substance with a high potential for abuse, no currently accepted medical use in treatment in the U.S., and a lack of accepted safety for use under medical supervision.
2 unchanged sentences
Food and Drug Administration (“ FDA ”) has not approved marijuana as a safe and effective drug for any indication.
−Removed: Moreover, under the Agriculture Improvement Act of 2018 (commonly referred to as the 2018 Farm Bill), marijuana remains a Schedule I controlled substance under the Controlled Substances Act, with the exception of hemp and extracts derived from hemp.
−Removed: State laws regulating cannabis are in direct conflict with the Controlled Substances Act.
+Added: Moreover, under the Agriculture Improvement Act of 2018 (commonly referred to as the 2018 Farm Bill), marijuana remains a Schedule I controlled substance under the CSA, with the exception of hemp and extracts derived from hemp.
+Added: Effective November 12, 2026, however, the definition of “hemp” is set to be narrowed substantially.
+Added: Under the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, the new definition of “hemp” will include only products with a concentration of no more than 0.3 percent of any THC (rather than delta-9 THC) on a dry weight basis.
+Added: This will result in excluding most, if not all, intoxicating hemp products from the definition of “hemp,” thereby subjecting such products to Schedule I restrictions as “marijuana.” Congress could still act to reverse course or delay the impending effective date of the change, as demonstrated by various pending legislation on this topic.
+Added: State laws regulating cannabis are in direct conflict with the CSA.
Although certain states and territories of the U.S.
1 unchanged sentence
federal law, the possession, use, cultivation, and transfer of cannabis and any related drug paraphernalia is illegal;
−Removed: any such acts are criminal acts under federal law under the Controlled Substances Act.
+Added: any such acts are criminal acts under federal law under the CSA.
+Added: Notwithstanding the foregoing, since 2014, Congress has included language in spending bills under what is known as the Rohrabacher-Farr (or Rohrabacher-Blumnauer) amendment that prohibits the Department of Justice (the “ DOJ ”) from expending resources to interfere with the implementation of state medical cannabis laws.
While our activities comply with applicable state and local laws, strict adherence to those laws does not absolve the Company of liability under federal law nor provide a defense against federal enforcement actions.
+Added: Furthermore, if Congress were to change its mind regarding the historical protections afforded to state medical cannabis regimes, the Company could face additional potential liability.
There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not restrict the applicability of such laws within their jurisdictions.
−Removed: Unless and until the Congress amends the Controlled Substances Act with respect to cannabis—of which the timing and scope are uncertain—there is a risk that federal authorities may enforce current federal law.
−Removed: We continue to monitor
−Removed: compliance on an ongoing basis in accordance with our compliance program and standard operating procedures.
+Added: Unless and until the Congress amends the CSA with respect to cannabis—of which the timing and scope are uncertain even after President Trump signed an executive order on December 18, 2025, which, among other things, directed “[t]he Attorney General to take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner”—there is a risk that federal authorities may enforce current federal law, especially as it relates to adult-use cannabis activities.
+Added: We continue to monitor compliance on an ongoing basis in accordance with our compliance program and standard operating procedures.
Although our operations are in material compliance with all applicable state laws, regulations and licensing requirements, they remain subject to federal law.
−Removed: If the Department of Justice (the “ DOJ ”) were to aggressively pursue debt or equity owners of cannabis-related business and if U.S.
−Removed: Attorneys acted accodingly, the Company could face:
+Added: If the DOJ were to aggressively pursue debt or equity owners of adult-use cannabis-related business, or if Congress failed to continue to pass measures to protect state-legal medical cannabis operations from such enforcement, and if U.S.
+Added: Attorneys acted accordingly, the Company could face:
(i) seizure of its cash and other assets used to support, or derived from, its cannabis subsidiaries;
−Removed: and (ii) the arrest of its employees, directors, officers, managers and investors, who could face charges of ancillary criminal violations of the Controlled Substances Act for aiding, abetting, and conspiring to violate the Controlled Substances Act by virtue of providing financial support to state-licensed or permitted cultivators, processors, distributors and/or retailers of cannabis.
+Added: and (ii) the arrest of its employees, directors, officers, managers and investors, who could face charges of ancillary criminal violations for aiding, abetting, and conspiring to violate the CSA by virtue of providing financial support to state-licensed or permitted cultivators, processors, distributors and/or retailers of cannabis.
Additionally, as affirmed by U.S.
Customs and Border Protection, non-citizen employees, directors, officers, managers, and investors in cannabis-related businesses face the risk of being barred from entry into the U.S.
−Removed: Department of Justice and Attorney General Memorandums
+Added: Department of Justice and Attorney General Memoranda
In August 2013, then-Deputy Attorney General James Cole authored a memorandum (the “ Cole Memorandum ”) addressed to all United States district attorneys acknowledging that, notwithstanding the designation of cannabis as a controlled substance, several states had enacted laws relating to cannabis for medical purposes.
15 unchanged sentences
● The activities relating to cannabis businesses adhere to the scope of the licensing obtained for such businesses.
−Removed: For example, in the states where only medical cannabis is permitted, the products are only sold to patients who hold the necessary documentation to permit the possession of cannabis.We only work through licensed operators, which must pass a range of requirements, adhere to strict business practice standards, and be subjected to strict regulatory oversight whereby sufficient checks and balances ensure that no revenue is distributed to criminal enterprises, gangs, and cartels.
+Added: For example, in the states where only medical cannabis is permitted, the products are only sold to patients who hold the necessary documentation to permit the possession of cannabis.
+Added: We only work through licensed operators, which must pass a range of requirements, adhere to strict business practice standards, and be subjected to strict regulatory oversight whereby sufficient checks and balances ensure that no revenue is distributed to criminal enterprises, gangs, and cartels.
● We conduct reviews of products and product packaging to ensure that the products comply with applicable regulations and contain necessary disclaimers about the contents of the products to prevent adverse public health consequences from cannabis use and prevent impaired driving.
● Our subsidiaries have implemented inventory-tracking systems and necessary procedures to ensure that inventory is effectively tracked, and the diversion of cannabis and cannabis products is prevented.
+Added: On May 16, 2024, the Drug Enforcement Administration (“ DEA ”) issued a Notice of Proposed Rulemaking (“ NPRM ”) to reschedule marijuana from Schedule I to Schedule III under the CSA.
+Added: Following the NPRM, the DEA received tens of thousands of comments, and as of this filing, an administrative hearing on the rulemaking remains pending.
+Added: On December 18, 2025, President Trump issued an executive order directing the DOJ to move forward with rescheduling marijuana to Schedule III as quickly as possible, consistent with federal law.
+Added: In the wake of the recent executive order, it still remains to be seen whether the administration will continue the process initiated by the 2024 NPRM or issue a new NPRM altogether.
+Added: Rescheduling to Schedule III would not automatically deem state cannabis regimes federally compliant.
+Added: Following rescheduling, the CSA’s restrictions would still apply to dealing in cannabis as a Schedule III substance, albeit with reduced potential penalties relative to dealing in a Schedule I substance.
+Added: Rescheduling would also allow a potential pathway to federally legalize medical marijuana, although this would require approval by the FDA of cannabis and cannabis-derived products, as well as alignment of state regimes with federal requirements.
+Added: Importantly, however, rescheduling to Schedule III should allow cannabis companies to deduct ordinary and necessary business expenses in the same manner currently allowed for other industries.
+Added: As further discussed below, under Section 280E of the U.S.
+Added: Internal Revenue Code, tax deductions and credits are disallowed for amounts paid or incurred in carrying on any business that consists of trafficking in Schedule I or II controlled substances.
+Added: Rescheduling would, therefore, represent a meaning opportunity for federal tax relief.
The risk of federal enforcement and other risks associated with the Company’s business are described under “ Item 1A.
3 unchanged sentences
Maryland Regulatory Landscape
−Removed: Maryland first enacted legal protections for medical cannabis patients in 2003, creating an affirmative defense for patients charged with possession of less than one ounce of cannabis.
+Added: Maryland first enacted legal protections for medical cannabis patients in 2003, setting the maximum penalty in such cases at a $100 fine.
+Added: In 2011, Maryland created an affirmative defense for patients with debilitating medical conditions charged with possession of less than one ounce of cannabis.
In 2013, lawmakers expanded the affirmative defense to protect cannabis caregivers, authorized the use of marijuana for investigational medical purposes, and established the Natalie M.
−Removed: LaPrade Medical Marijuana Commission (“ MMCC ”) to develop, approve and monitor cannabis academic study programs.
+Added: LaPrade Maryland Medical Cannabis Commission (“ MMCC ”) to develop, approve and monitor cannabis academic study programs.
In 2014, legislation was enacted to establish a state-regulated medical cannabis program and expand the MMCC’s regulatory authority.
−Removed: the law was signed in April 2014, and the program became operational on December 1, 2017.
−Removed: The market is divided into three primary classes of licenses:
+Added: Maryland’s medical cannabis program became operational on December 1, 2017.
+Added: The market at that time was divided into three primary classes of licenses:
dispensary, cultivation, and processing.
−Removed: Pre-approvals for medical cannabis dispensary license were issued to 102 dispensaries from a pool of over 800 applicants, while 15 processing licenses were awarded from 124 applicants and 15 cultivation licenses from 145 applicants.
+Added: Pre-approvals for medical cannabis dispensary licenses were issued to 102 dispensaries from a pool of over 800 applicants, while 15 processing license pre-approvals were awarded from 124 applicants and 15 cultivation license pre-approvals from 145 applicants.
The medical cannabis program was designed to allow access to medical cannabis for patients with qualifying medical conditions, including chronic pain, nausea, seizures, glaucoma, and post-traumatic stress disorder (PTSD).
MaryMed LLC, an indirect wholly-owned subsidiary of Vireo, was awarded a vertically integrated medical marijuana license in 2016.
−Removed: In April 2018, Maryland lawmakers agreed to expand the state’s medical cannabis industry by adding another 20 licenses —7 for cultivation and 13 for processing.
+Added: In April 2018, Maryland expanded the state’s medical cannabis industry by adding another 20 licenses — 7 for cultivation and 13 for processing.
Permitted products for sale and consumption include oil-based formulations, dry flower, edibles, and other concentrates.
−Removed: Maryland voters approved a referendum to legalize adult-use cannabis on November 8, 2022.
+Added: Maryland voters approved a referendum to legalize adult-use cannabis in November 2022.
In May 2023, the Maryland General Assembly repealed the MMCC's authorization under the Cannabis Reform Act of 2023, and the MMCC’s functions were transferred to the newly established Maryland Cannabis Administration (the “ MCA ”).
Adult-use legalization went into effect on July 1, 2023.
+Added: This legislation provided a two-round process by which the MCA would issue cannabis licenses to growers (i.e., cultivators), processors, and dispensaries, as well as two additional license types:
+Added: incubator space (i.e., a space in which another licensee may operate) and on-site consumption.
+Added: In April 2024, with HB 253, Maryland lawmakers added seeds, seedlings, immature plants, and clones to the definition of “cannabis,” and required “cannabis nurseries” (which sell such items to cannabis licensees) to register with the MCA.
+Added: In April 2025, with SB 215, the General Assembly indefinitely delayed the rollout of on-site consumption licenses and preemptively limited on-site consumption to include only edibles and cannabinoid beverages.
Licenses in Maryland
−Removed: As of March 4, 2025, we operate two (2) medical and adult-use dispensaries, a cultivation license, and a processor license in the State of Maryland.
−Removed: The Company also manages two (2) medical and adult-use dispensaries pursuant to management agreements with licensees.
+Added: As of March 1, 2026, we operate two (2) medical and adult-use dispensary licenses, a cultivation license, and a processor license in the State of Maryland.
+Added: The Company also manages two (2) medical and adult-use dispensary licenses pursuant to management agreements with those licensees.
Maryland Licenses and Regulations
Maryland licenses are valid for five years after required fees are paid and provided that the business remains in good standing.
+Added: For any medical cannabis dispensaries that converted to dual-licensed (medical and adult-use) status, those dispensaries are subject to a five-year restriction on transferring ownership or control of their license.
+Added: This effectively creates a moratorium on selling or transferring control for most operators until July 1, 2028.
Renewal requests are typically communicated through email from the MCA and include a renewal form.
5 unchanged sentences
Minnesota legalized medical marijuana on May 29, 2014, when Governor Mark Dayton signed the Minnesota Medical Cannabis Act into law.
−Removed: The state’s medical program officially launched on July 1, 2015, allowing registered patients to access cannabis products from state-approved dispensaries to treat a set of nine qualifying medical conditions, which has since been expanded to 15.
−Removed: The program was regulated and administered by the Minnesota Department of Health, which oversaw all cultivation, production, and distribution facilities.
+Added: The state’s medical program officially launched on July 1, 2015, allowing registered patients to access cannabis products from state-approved dispensaries to treat a set of nine qualifying medical conditions, which has since been expanded to 19, with a catch-all provision that recognizes any condition for which a patient’s health care practitioner has recommended, approved, or authorized the use of cannabis by that individual to treat the condition.
+Added: The medical program was regulated and administered by the Minnesota Department of Health, which oversaw all cultivation, production, and distribution facilities.
The state authorized only two vertically integrated medical cannabis manufacturer licenses—LeafLine Labs and Minnesota Medical Solutions.
Initially, each manufacturer was permitted up to four distribution facilities across the state.
−Removed: Minnesota now allows a manufacturer to operate eight distribution facilities, which may include the manufacturer’s single location for cultivation, manufacturing, packaging, and processing, although including that location is not required.
+Added: Minnesota later allowed a manufacturer to operate eight distribution facilities, but the restriction on manufacturers’ operation of distribution facilities was repealed, effective December 1, 2025.
Medical cannabis was initially provided to patients in several forms, including dried cannabis, liquid formulations, pills, and topical (lotions, balms, and patches);
−Removed: it was also delivered via vaporized delivery methods that did not require the use of dried leaves, as well as in water-soluble cannabinoid multi-particulates ( e.g.
+Added: it was also delivered via vaporized delivery methods that did not require the use of dried leaves, in water-soluble cannabinoid multi-particulates ( e.g.
, granules, powders, and sprinkles) and orally dissolvable products ( e.g.
1 unchanged sentence
Minnesota has implemented a process for monitoring and evaluating the health impacts of medical cannabis on patients, which will be used to help patients and health professionals grow their understanding of the benefits, risks, and side effects of medical cannabis.
+Added: On July 1, 2022, food and beverages containing hemp-derived THC became legal in Minnesota.
+Added: Serving and total package limits were applied to any such products.
+Added: Earlier in 2022, a new law went into effect allowing medical cannabis patients to access dried cannabis flower.
On May 30, 2023, the Governor of Minnesota signed into law House File No.
100 ") of the 2022 Session, Chapter 63, a bill of an act relating to adult-use cannabis.
−Removed: As a result, many marijuana reform laws went into effect August 1, 2023, including adult use legalization, rescheduling under Minnesota's Controlled Substance Act, allowing 21 years of age or older to possess or transport two ounces or less of adult-use cannabis, or eight grams or less of adult-use cannabis concentrate, edible cannabis products or lower-potency hemp edibles infused with a combined total of 800 milligrams or less of tetrahydrocannabinol, and legalizing home grow of up to four mature plants per residence.
+Added: As a result, many marijuana reform laws went into effect August 1, 2023, including adult use legalization, rescheduling under Minnesota's Controlled Substance Act, allowing persons 21 years of age or older to possess or transport two ounces or less of adult-use cannabis, or eight grams or less of adult-use cannabis concentrate, edible cannabis products or lower-potency hemp edibles infused with a combined total of 800 milligrams or less of tetrahydrocannabinol, and legalizing home grow of up to four mature plants per residence.
On July 1, 2024, pursuant to H.F.
100, the powers and duties of the Minnesota Department of Health with respect to the medical cannabis program were transferred to the Minnesota Office of Cannabis Management.
−Removed: The adult-use cannabis program is expected to commence in 2025.
+Added: Effective May 23, 2025, medical cannabis patients from other states may purchase from Minnesota-licensed dispensaries, subject to additional compliance requirements for the dispensary.
+Added: Retail sales under the adult-use cannabis program commenced in September of 2025.
Licenses and Permits in Minnesota
−Removed: Today, Vireo Health of Minnesota, LLC (“ Vireo Minnesota ”) (f/k/a Minnesota Medical Solutions and an indirect wholly-owned subsidiary of Vireo) is one of two licensed medical cannabis manufacturers and is responsible for cultivating, processing, and dispensing medical cannabis to registered patients through its eight medical marijuana dispensaries in the state.
+Added: Today, Vireo Health of Minnesota, LLC (“ Vireo Minnesota ”) (f/k/a Minnesota Medical Solutions and an indirect wholly-owned subsidiary of Vireo) is one of two medical cannabis combination licensees in the state, cultivating, processing, and dispensing medical cannabis to registered patients through its eight medical cannabis dispensaries in the state.
Our manufacturer license was awarded in 2015 through merit-based license application processes.
1 unchanged sentence
We believe that our medical and scientific expertise helped us develop a competitive advantage in the marketplace.
−Removed: Vireo Minnesota holds one vertically-integrated medical cannabis license to operate one cultivation and production facility in Otsego, MN and eight retail medical cannabis dispensaries in the state of Minnesota, located in Blaine, Bloomington, Burnsville, Hermantown, Rochester, Minneapolis, Moorhead, and Woodbury.
+Added: Vireo Minnesota holds one vertically-integrated medical cannabis combination license to operate one cultivation and production facility in Otsego, MN and eight retail medical cannabis dispensaries in the state of Minnesota, located in Blaine, Bloomington, Burnsville, Hermantown, Rochester, Minneapolis, Moorhead, and Woodbury.
+Added: By virtue of its medical cannabis combination business, is approved to engage in:
+Added: medical and adult-use cannabis cultivation, manufacturing, and retail sales;
+Added: extraction/concentration and medical cannabis processing activities;
+Added: handling of cannabinoid products;
+Added: and internal transport.
Minnesota Licenses and Regulations
We currently operate eight retail dispensaries and one cultivation and production facility of approximately 90,000 square feet.
−Removed: Recent changes to the state’s qualifying conditions for medical cannabis patients have contributed to increases in patient enrollment.
−Removed: Minnesota state licenses are renewed every two years.
+Added: Changes to the state’s qualifying conditions for medical cannabis patients have contributed to increases in patient enrollment.
+Added: Minnesota state licenses are renewed every year.
Provided that the requisite renewal fees are paid, the renewal application is submitted in a timely manner, and no material violations are noted, the Company expects to receive the applicable renewed license in the ordinary course of business.
11 unchanged sentences
The Marihuana Regulation & Taxation Act was signed into law on March 31, 2021, legalizing adult-use cannabis in New York State.
−Removed: MRTA established the OCM, governed by a Cannabis Control Board to comprehensively regulate adult-use, medical, and hemp cannabis.
+Added: MRTA established the Office of Cannabis Management (“ OCM ”), governed by a Cannabis Control Board to comprehensively regulate adult-use, medical, and hemp cannabis.
The OCM released its final rules and regulations governing the adult-use industry in September 2023, and has begun to issue licenses.
4 unchanged sentences
These designated caregivers must also register with the NYSDOH to obtain their own registry identification.
−Removed: There are ten registered organizations, each holding a vertically integrated license permitting the cultivation, manufacture, transport, distribution, and dispensation of medical cannabis.
−Removed: Registered organizations may only manufacture medical cannabis products in forms approved by the Office of Cannabis Management (the “ OCM ”).
−Removed: Approved forms currently include whole flower, metered liquid or oil preparations, solid and semisolid preparations ( e.g ., capsules, chewable and effervescent tablets, lozenges), oral sprays, oral powders, metered ground plant preparations, and transdermal patches.
+Added: All registered organizations can hold a vertically integrated license permitting the cultivation, manufacture, transport, distribution, and dispensation of medical cannabis.
+Added: Registered organizations may only manufacture medical cannabis products in forms approved by the OCM.
+Added: Approved forms currently include concentrates ( e.g.
+Added: , shatters, waxes, resins and any other concentrates that are not gel-based or water soluble);
+Added: edibles ( e.g.
+Added: , capsules, beverages, tablets, tinctures, baked goods, gummies, chocolates, and any other edibles);
+Added: and flower products ( e.g.
+Added: whole flower, ground flower, shake, pre-rolls, and any other flower);
+Added: vaporization cartridges or single use pens;
+Added: and topicals ( e.g.
+Added: , transdermal patches).
Each registered organization may have up to four dispensing facilities, owned and operated by the registered organization, where approved medical cannabis products will be dispensed to certified patients or their designated caregivers, who have registered with the Department.
+Added: A registered organization may have four additional dispensing facilities, but only if the first two additional dispensing facilities are located in underserved or unserved geographic locations, as determined by OCM.
Dispensing facilities must report dispensing data to the New York State Prescription Monitoring Program Registry and consult the registry prior to dispensing approved medical cannabis products to certified patients or their designated caregivers.
+Added: In November 2025, the state enacted S3294A, which included various updates to the medical cannabis program that could serve to increase access to medical dispensaries.
+Added: Under the new law, out-of-state medical cannabis patients are generally permitted to purchase from New York dispensaries.
+Added: This law also eliminated the requirement for patients to obtain registry identification cards, instead allowing patients to purchase from medical dispensaries using a valid government-issued photo identification and a valid certification from a medical practitioner.
Licenses and Permits in New York
In New York, we were one of the original five registered organizations, placing second in the initial selection process, and are currently one of ten registered organizations (vertically integrated medical cannabis licensees) in the state.
−Removed: On July 11, 2024, Vireo New York was issued a registered organization non-dispensing license, authorizing the company to operate a medical and adult-use cultivation/manufacturing facility and up to four medical marijuana dispensaries.
+Added: On July 11, 2024, Vireo New York was issued a registered organization non-dispensing license, authorizing the company to operate a medical and adult-use cultivation/manufacturing facility and up to four medical cannabis dispensaries.
All licenses are, as of the date hereof, active with the State of New York.
The licenses are independently issued for each approved activity for use at our facilities in New York.
−Removed: Today, through our subsidiary Vireo Health New York, we hold one of ten vertically integrated cannabis licenses.
−Removed: We currently have a cultivation and processing facility in Johnstown, NY and four dispensaries throughout the State in New York City (Queens County), Binghamton, White Plains and Albany.
+Added: Today, through our subsidiary Vireo Health New York, we hold one vertically integrated cannabis license.
+Added: We currently have a cultivation and processing facility in Johnstown, NY and four dispensaries throughout the State in New York City (Queens County), Johnson City, White Plains and Albany.
We also operate a home-delivery service based out of our Queens dispensary.
−Removed: Our New York cultivation and processing facility is approximately 21 acres and compromised of 13,650 square foot of indoor cultivation space, 38,304 square feet of greenhouse cultivation space, and 7,350 square feet of laboratory and processing space.
−Removed: The facility has been in continuous production and sale of cannabis since January 2016.
−Removed: In addition, on an adjacent parcel to the existing facility, we have approximately 30,000 square feet of operational cultivation and processing space, and approximately 45,000 square feet of incremental cultivation and processing facility under construction, all of which is housed inside a building exceeding 300,000 square feet.
While we believe the long-term opportunity in New York is substantial, recent performance has been impacted by neighboring states transitioning to adult-use jurisdictions, as well as by increasing competition from other developing operators.
5 unchanged sentences
New York Reporting Requirements
−Removed: The state of New York uses BIOTRACKTHC © as the state’s cultivation and production computerized T&T system.
−Removed: Leaf Logix by Dutchie is used as state’s point of sale T&T system.
−Removed: Individual licensees are required to push data to the state to meet all reporting requirements.
+Added: The state of New York Marijuana Enforcement Tracking Regulation and Compliance system (METRC) as the state’s computerized T&T system for seed-to-sale.
+Added: Individual licensees whether directly or through third-party integration systems are required to push data to the state to meet all reporting requirements.
+Added: We use a third-party application for our computerized seed to sale software, which integrates with the state’s Metrc program and captures the required data points for cultivation, manufacturing and retail as required.
+Added: Missouri Regulatory Landscape
+Added: In 2014, the Missouri Senate passed Senate Bill 491.
+Added: The legal effect of SB 491 was to reduce the punishments and penalties that marijuana-related offenses had hitherto attracted.
+Added: SB 491 also created a new classification for marijuana-related felonies to be known as Class E and a new classification for marijuana-related misdemeanors to be known as Class D.
+Added: Individuals caught in possession of marijuana weighing 10 grams or less would under SB 491 be charged with the lesser Class D misdemeanor rather than the more serious Class A misdemeanor.
+Added: In the same year, 2014, the Missouri Medical Marijuana Bill, HB 2238, was passed into law.
+Added: This bill made it legal in Missouri to use an active ingredient in marijuana, cannabidiol, to treat patients suffering from epileptic seizures.
+Added: Patients were required to obtain a registration card by providing a signed statement from a neurologist attesting to their epilepsy and their potential to benefit from treatment with hemp extract.
+Added: The bill, accordingly, excused card-holders from the punishments and penalties for possession or use of hemp extract, provided that their possession or use was in compliance with the bill.
+Added: In November 2018, the Missouri electorate voted to pass Amendment 2.
+Added: It made the use of marijuana for medical purposes legal in Missouri and was enshrined as Article XIV of the state constitution.
+Added: Article XIV gave leave to Missouri residents to access medical marijuana, provided they met the criteria.
+Added: The article also included requirements for the cultivation, testing, and dispensation of medical marijuana.
+Added: Notably, the article also includes a tax on medical marijuana, charged at four percent of the retail price.
+Added: On November 8, 2022, Amendment 3 appeared on the ballot, raising the question of whether to legalize recreational marijuana in the state.
+Added: The amendment passed, and provisions for a recreational marijuana program were enshrined as a newly created Section 2 of Article XIV one month later.
+Added: This legalized recreational use of marijuana in Missouri for adults aged 21 or older.
+Added: The Missouri Department of Health and Senior Services (“ MDHSS ”) began granting requests from existing medical marijuana dispensaries to become comprehensive (i.e., medical and adult-use) facilities on February 3, 2023.
+Added: Since the establishment of Article XIV, Section 2, the frameworks for both medical and adult-use marijuana remain in place, with statutory and regulatory implementation taking place shortly thereafter.
+Added: For instance, the MDHSS now requires all employees, contractors, owners, and volunteers of marijuana facilities to submit fingerprints to the Missouri State Highway Patrol for a background check.
+Added: Within the MDHSS, the Division of Cannabis Regulation has implemented regulations covering a wide range of industry medical and adult-use industry activity, including testing, facility security, packaging/labeling, seed-to-sale tracking, transportation and storage, and waste disposal.
+Added: Licenses and Permits in Missouri
+Added: We currently operate one cultivation and processing facility, a second processing facility, and eleven retail dispensaries.
+Added: Our cultivation license expires in October 2027.
+Added: All dispensary licenses expire in January 2029, with the exception of the license for the Bridgeton, MO location which expires in October 2027.
+Added: The processing manufacturing licenses expire in January 2029.
+Added: The transport licenses expire in December 2028.
+Added: Provided that the requisite renewal fees are paid, the renewal application is submitted in a timely manner, and no material violations are noted, the Company expects to receive the applicable renewed license in the ordinary course of business.
+Added: While the Company’s compliance controls are designed to mitigate the risk of any material violations, there is no assurance that our license will be renewed in a timely manner.
+Added: Any unexpected delays or costs in the renewal process could materially and adversely affect our operations and financial results.
+Added: Missouri Reporting Requirements
+Added: The State of Missouri uses Marijuana Enforcement Tracking Regulation and Compliance system (METRC) to provide the state’s seed-to-sale system for end-to-end plant and product monitory, and Tyler Technologies provides the licensing platform support and individual cardholder registration, credentialing and licensing.
+Added: Nevada Regulatory Landscape
+Added: Medical marijuana became legal in Nevada in 2000.
+Added: Individuals with certain medical conditions, such as anxiety, cancer, glaucoma, HIV, seizures, autism, and chronic pain may possess up to 2.5 ounces of marijuana every 14 days.
+Added: They can also cultivate up to 12 marijuana plants.
+Added: However, marijuana cultivation is prohibited for patients living within 25 miles of a licensed dispensary.
+Added: Qualifying patients must register with the Division of Public and Behavioral Health (“DPBH” and obtain a medical marijuana card.
+Added: Medical marijuana approved by the DPBH includes concentrates, topicals, edibles, and flowers.
+Added: In November 2016, Nevadans voted in favor of Question 2, which sought to legalize, regulate and tax recreational marijuana for persons aged 21 or older.
+Added: Recreational cannabis became legal in Nevada on January 1, 2017, and the first licensed sale occurred in the state on July 1, 2017.
+Added: This allowed adults to buy and possess up to 1 oz.
+Added: of cannabis flower and one-eighth of an ounce of cannabis concentrate.
+Added: In June 2021, Governor Steve Sisilak signed Assembly Bill 341 into law, permitting the licensing and regulation of cannabis consumption lounges.
+Added: The law allows the purchase and public consumption of marijuana at designated marijuana lounges.
+Added: In 2022, the Cannabis Compliance Board (“ CCB ”) issued regulations for the licensing and operations of marijuana consumption lounges and issued the first cannabis consumption license in December 2022.
+Added: The first marijuana consumption lounge in Nevada became operational in 2023.
+Added: In June 2023, Governor Joe Lombardo signed Senate Bill 277 to raise the limits on possession for adult-use cannabis.
+Added: The new limits are 2.5 ounces of cannabis flower and one-quarter of an ounce of concentrate.
+Added: This legislation also deems each adult-use cannabis establishment to be a dual licensee, thereby authorizing the establishment to engage in medical cannabis activities as if the adult-use establishment held a medical cannabis license of the same type.
+Added: Thus, adult-use licensees no longer require a separate medical license to operate in the capacity of a medical cannabis licensee.
+Added: Licenses and Permits in Nevada
+Added: We currently operate twelve retail dispensaries, and one retail, cultivation and production facility.
+Added: Nevada state cannabis establishment licenses are renewed every year.
+Added: Provided that the requisite renewal fees are paid, the renewal application is submitted in a timely manner, and no material violations are noted, the Company expects to receive the applicable renewed license in the ordinary course of business.
+Added: While the Company’s compliance controls are designed to mitigate the risk of any material violations, there is no assurance that our license will be renewed in a timely manner.
+Added: Any unexpected delays or costs in the renewal process could materially and adversely affect our operations and financial results.
+Added: Nevada Reporting Requirements
+Added: The State of Nevada uses Marijuana Enforcement Tracking Regulation and Compliance system (METRC) as the state’s inventory tracking and compliance system for marijuana establishments.
+Added: Effective November 1, 2017, all medical and adult-use marijuana establishments in Nevada must report their establishment data to the state of Nevada via METRC.
+Added: This includes cultivators, product manufacturers, testing labs, distributors, dispensaries/retail stores, and consumption lounges.
+Added: Utah Regulatory Landscape
+Added: In 2014, Utah HB 105 was passed by the state, creating a legal right for persons diagnosed by neurologists with intractable epilepsy and registered with the state to have and use hemp extracts to treat their conditions.
+Added: Per HB 105, hemp extracts must contain a minimum 15% CBD and but no more than 0.3% THC.
+Added: The extracts must also be free of any form of psychoactive substance.
+Added: In 2017, Utah HB 130 was passed, allowing persons with approvals from an institutional review board of the United States Department of Health and Human Services to import and distribute cannabis and cannabis products for purposes of conducting a research study.
+Added: In November 2018, Utah voters approved Proposition 2, allowing patients to have and use medical cannabis subject to certain restrictions.
+Added: The law also allowed licensed facilities to cultivate, process, test, and sell medical cannabis.
+Added: In December 2018, the Utah governor signed into law HB 3001 (i.e., the Utah Medical Cannabis Act), which included provisions to ease the requirements for renewing medical cannabis cards, establish stricter qualifications for caregivers and guardians, provide employment protections for patients, and regulate the consumption of medical marijuana.
+Added: In 2019, Utah lawmakers approved SB 1002 to increase the number of medical cannabis pharmacies to 14.
+Added: In 2020, Governor Herbert signed SB 121, overhauling the state cannabis laws.
+Added: First, SB 121 eliminates raw cannabis flower "blister" packaging requirements for raw cannabis flower.
+Added: The law also changes provisions related to driving under the influence of cannabis, such that drivers will no longer be penalized solely for having inactive cannabis metabolites.
+Added: The apparent rationale for this change is that the presence of metabolites does not necessarily indicate intoxication.
+Added: SB 121 also extends medical cannabis eligibility to include patients suffering from conditions other than the previously approved diseases and conditions.
+Added: In the same year, Governor Herbert also signed HB 425 into law, delaying until the end of 2020 the requirement from 2018 HB 3001 for patients to obtain medical cannabis cards from the Utah Department of Health.
+Added: Under HB 425, patients could continue using recommendations in the form of a doctor's letter.
+Added: In 2021, Governor Spencer Cox signed SB 192, making the following amendments to the Utah Medical Cannabis Act:
+Added: (a) the Utah Department of Health was authorized to issue a 15th Medical Cannabis pharmacy license, (b) medical cannabis transactions are to be reviewed by Pharmacy Medical Providers, (c) medical cannabis card holders are not permitted to alter or remove product processor’s labels from medical cannabis containers, and (d) Qualified Medical Providers (“ QMPs ”) now have the option to submit treatment and medication history to the state’s Electronic Verification System, if the QMP determines the information is relevant.
+Added: Also in 2021, Governor Cox signed SB 170, allowing podiatrists to become QMPs and recommend medical cannabis within the course of their practice.
+Added: QMPs who are PAs (physician assistants) also no longer require supervision from physicians who are QMPs.
+Added: In 2022, the state expanded access to medical cannabis with SB 195.
+Added: In relevant part, this bill mandated that hospice programs provide at least one QMP, thereby making medical cannabis recommendations more readily available in the hospice setting.
+Added: In 2025, Governor Cox signed HB 357, which notably repealed the requirement for a practitioner to register with the state as a QMP before recommending medical cannabis.
+Added: Instead, the same types of licensed professionals—physicians, PAs, and podiatrists—may recommend medical cannabis if they are duly licensed, complete four hours of continuing medical
+Added: education specific to medical cannabis, and acknowledge completion of such training every two years in a communication to the Utah Department of Health and Human Services.
+Added: In 2025, Governor Cox also signed HB 54, increasing the number of medical cannabis pharmacies to 17.
+Added: Licenses and Permits in Utah
+Added: We currently operate one co-located cultivation and processing facility, one outdoor cultivation facility consisting of a warehouse used for storage and other post-harvest medical cannabis activities and a 2.4 acre outdoor field, one home delivery pharmacy location, and one medical cannabis courier location (co-located with the pharmacy).
+Added: Utah state licenses are renewed every year.
+Added: Provided that the requisite renewal fees are paid, the renewal application is submitted in a timely manner, and no material violations are noted, the Company expects to receive the applicable renewed license in the ordinary course of business.
+Added: While the Company’s compliance controls are designed to mitigate the risk of any material violations, there is no assurance that our license will be renewed in a timely manner.
+Added: Any unexpected delays or costs in the renewal process could materially and adversely affect our operations and financial results.
+Added: Utah Reporting Requirements
+Added: Leaf Data Systems, otherwise known as MJ Freeway, was selected by Utah in 2019 as the initial medical cannabis seed-to-sale tracking system.
+Added: In 2024, Utah switched to an updated Electronic Verification System (EVS).
+Added: EVS is used to manage medical cannabis card applications and other recordkeeping for patients and providers.
Compliance with Environmental Laws
6 unchanged sentences
Compliance Program and Oversight
−Removed: Under the oversight of our Outside General Counsel, our legal and compliance team develops, maintains, and implements our comprehensive compliance program.
−Removed: In addition to our Outside General Counsel, we engage state-specific regulatory compliance counsel and other legal specialists as needed.
+Added: Under the oversight of our General Counsel, our legal and compliance team develops, maintains, and implements our comprehensive compliance program.
+Added: In addition to our General Counsel and legal and compliance team, we engage state-specific regulatory compliance counsel and other legal specialists as needed.
Our team is responsible for training cultivation, production, and dispensary managers, employees, department leaders, and other designated persons on state and local laws and regulations.
6 unchanged sentences
In addition to scheduled audits, our security and staff perform unscheduled, unannounced audits to prevent complacency.
−Removed: Adherence to our standard operating procedures is mandatory, ensuring compliance with all applicable state and local laws, regulations, ordinances, licenses, and other requirements.
+Added: Adherence to our standard operating procedures is mandatory, ensuring compliance with all applicable state and local laws, regulations, ordinances, licenses,
+Added: and other requirements.
We conduct internal inspections to verify adherence and resolve any issues quickly and thoroughly.
21 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.